Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apis mellifera venom
- Development stage
- Phase 4
- Lead developer
- Stallergenes Greer
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intradermal, Topical, Intramuscular, Intraarticular
01
Overview
Apis mellifera venom, or honey bee venom, is a complex biological substance containing various bioactive peptides and enzymes, most notably melittin, apamin, and phospholipase A2. It is primarily developed as a purified, standardized preparation for therapeutic use. In clinical settings, it is being investigated for its anti-inflammatory and analgesic properties in conditions such as osteoarthritis and multiple sclerosis, and for its neuroprotective potential in Parkinson's disease. The venom's mechanism of action includes the modulation of inflammatory cytokines and the blockade of small conductance calcium-activated potassium (SK) channels. Companies like Apimeds Pharmaceuticals US and Allergopharma are leading the clinical development of purified bee venom products for systemic and local administration.
- Brand names
- Apitox
- Other names
- Honey bee venomBee venom蜂毒
02
Targets
MRC1 (Mannose Receptor C-type 1)
Beyond the preview
Go deeper on apis mellifera venom.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apis mellifera venom.